[Articles] Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Related Posts

• Optimal Procedures for [177Lu]Lu-PSMA-617 Therapy in US Prostate Cancer Centers

  KEY TAKEAWAYS This phase 3 study outlined the requirements and best practices for establishing safe…

• Exploring the Efficacy of 177Lu-PSMA-617 in Metastatic Castrate-Resistant Prostate Cancer

  KEY TAKEAWAYS Phase 3 VISION trial evaluated the effectiveness of 177Lu-PSMA-617 in combination with standard…

• Prostate Cancer Imaging Update: [⁸⁹Zr]Zr-PSMA-617 Insights

  KEY TAKEAWAYS The study aimed to investigate the efficacy of [89Zr]Zr-PSMA-617 PET/CT in characterizing indeterminate…